Gilead Sciences, Inc. GILD
150.93
1.24
0.83%
as of 25 Sep
- Market cap
- $183.2B
- P/E
- 0.0×
Follow GILD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Gilead Sciences, Inc. (GILD) Return on assets
Gilead Sciences, Inc.'s return on assets over the twelve months to 30 June 2026 was −6.17%, down 20.6 percentage points from fiscal 2025 (14.4%). Over the past ten years it has ranged from 0.19% (fiscal 2020) to 41.9% (fiscal 2015); the current reading is higher than 82% of that period. That is below the Drug Manufacturers General industry median of 2.76% and above the Healthcare sector median of −30.9%.
Return on assets, annual
Annual
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 14.4% | 13.63 |
| FY2024 | 0.79% | (8.25) |
| FY2023 | 9.04% | 2.04 |
| FY2022 | 7.00% | (2.13) |
| FY2021 | 9.13% | 8.94 |
| FY2020 | 0.19% | (8.41) |
| FY2019 | 8.60% | 0.46 |
| FY2018 | 8.14% | 0.87 |
| FY2017 | 7.27% | (17.57) |
| FY2016 | 24.8% | (17.09) |
Against its own ten years
Low 0.19%
High 41.9%
Ten-year median
8.60%
Current reading's percentile
82
Return on assets against peers
| Company | Return on assets |
|---|---|
| NVO Novo Nordisk A/S compare | 22.0% |
| NVS Novartis AG compare | 11.3% |
| BMY Bristol Myers Squibb Company compare | 10.2% |
| AMGN Amgen Inc. compare | 9.53% |
| AZN AstraZeneca PLC compare | 9.15% |
| GSK GSK PLC Sponsored ADR compare | 8.01% |
| SNY Sanofi compare | 3.21% |
| PFE Pfizer Inc. compare | 2.13% |
| GILD Gilead Sciences, Inc. | −6.17% |
| Drug Manufacturers General industry median | 2.76% |
| Healthcare sector median | −30.9% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on GILD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement